Complete Response Letters In Lieu Of Inspections: What To Expect During COVID-19

PS2008_Lab Workers_1355282012_1200.jpg

The US Food and Drug Administration confirmed in guidance published on 19 August that it will generally issue complete response letters to drug application sponsors when it has concerning information about their manufacturing facilities but cannot conduct a timely pre-approval inspection, or PAI, due to the novel coronavirus pandemic.

Alternatively, the agency said if it lacks adequate information to decide whether a facility is acceptable, it may defer action...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from International

More from Geography